ArticleJournal of clinical lipidology

Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.

Marja-Riitta Taskinen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.